Controls nausea and vomiting associated with certain types of anesthesia and surgery. ANDA 91179, held by Amneal Pharms Ny. Promethazine Hydrochloride.
As of Nov 16, 2026, ANDA 91179 (Promethazine Hydrochloride), held by Amneal Pharms Ny, was first approved by FDA on Dec 13, 2010, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Promethazine Hydrochloride Tablets are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions as adjunctive therapy to epinephrine and other standard measures after the acute manifestations have been controlled. Preoperative, postoperative and obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 2010 | Original application | Approved | None posted |
| Promethazine Hydrochloride12.5MG · tablet;oral | Promethazine Hydrochloride | Rx |
| Promethazine Hydrochloride25MG · tablet;oral | Promethazine Hydrochloride | Rx |
| Promethazine Hydrochloride50MG · tablet;oral | Promethazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters